Anti-aging play Unity raises $116M in series B

Unity Biotechnology Inc. (San Francisco, Calif.) raised $116 million in a series B round led by Arch Venture Partners and Baillie Gifford. New investors Fidelity, Partner Fund Management, Bezos Expeditions and existing investors Venrock, the WuXi PharmaTech Inc. subsidiary of New WuXi Life Science Ltd. (Shanghai, China), and Mayo Clinic also participated. According to BioCentury's BCIQ database, the financing is the 12th largest series B round since BioCentury started tracking financings in 1994.

Unity is developing small molecule therapies that selectively induce death of senescent cells to treat age-related diseases. President Nathaniel David declined to disclose the compounds' targets. ...